546 related articles for article (PubMed ID: 23998969)
1. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
3. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Dunbar RL; Nicholls SJ; Maki KC; Roth EM; Orloff DG; Curcio D; Johnson J; Kling D; Davidson MH
Lipids Health Dis; 2015 Sep; 14():98. PubMed ID: 26328624
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
Mozaffarian D; Maki KC; Bays HE; Aguilera F; Gould G; Hegele RA; Moriarty PM; Robinson JG; Shi P; Tur JF; Lapointe JF; Aziz S; Lemieux P;
JAMA Netw Open; 2022 Jan; 5(1):e2141898. PubMed ID: 34989797
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Jun JE; Jeong IK; Yu JM; Kim SR; Lee IK; Han KA; Choi SH; Kim SK; Park HK; Mok JO; Lee YH; Kwon HS; Kim SH; Kang HC; Lee SA; Lee CB; Choi KM; Her SH; Shin WY; Shin MS; Ahn HS; Kang SH; Cho JM; Jo SH; Cha TJ; Kim SY; Won KH; Kim DB; Lee JH; Lee MK
Diabetes Metab J; 2020 Feb; 44(1):78-90. PubMed ID: 31237134
[TBL] [Abstract][Full Text] [Related]
7. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
Morton AM; Furtado JD; Lee J; Amerine W; Davidson MH; Sacks FM
J Clin Lipidol; 2016; 10(6):1442-1451.e4. PubMed ID: 27919362
[TBL] [Abstract][Full Text] [Related]
8. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Offman E; Marenco T; Ferber S; Johnson J; Kling D; Curcio D; Davidson M
Vasc Health Risk Manag; 2013; 9():563-73. PubMed ID: 24124374
[TBL] [Abstract][Full Text] [Related]
9. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
Dogay Us G; Mushtaq S
Lipids Health Dis; 2022 Sep; 21(1):84. PubMed ID: 36050695
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial.
Stroes ESG; Susekov AV; de Bruin TWA; Kvarnström M; Yang H; Davidson MH
J Clin Lipidol; 2018; 12(2):321-330. PubMed ID: 29289538
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
[TBL] [Abstract][Full Text] [Related]
12. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.
Davidson MH; Phillips AK; Kling D; Maki KC
Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1045-54. PubMed ID: 25089906
[TBL] [Abstract][Full Text] [Related]
13. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
Roth EM; Bays HE; Forker AD; Maki KC; Carter R; Doyle RT; Stein EA
J Cardiovasc Pharmacol; 2009 Sep; 54(3):196-203. PubMed ID: 19597368
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
[TBL] [Abstract][Full Text] [Related]
15. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
Dunbar RL; Gaudet D; Davidson M; Rensfeldt M; Yang H; Nilsson C; Kvarnström M; Oscarsson J
Lipids Health Dis; 2020 May; 19(1):117. PubMed ID: 32473640
[TBL] [Abstract][Full Text] [Related]
16. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
Nicholls SJ; Lincoff AM; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Pedersen TR; Ridker PM; Ray K; Karlson BW; Lundström T; Wolski K; Nissen SE
Clin Cardiol; 2018 Oct; 41(10):1281-1288. PubMed ID: 30125052
[TBL] [Abstract][Full Text] [Related]
17. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
[TBL] [Abstract][Full Text] [Related]
18. A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States.
Lapointe JF; Harvey L; Aziz S; Jordan H; Hegele RA; Lemieux P
Clin Ther; 2019 Mar; 41(3):426-444. PubMed ID: 30799231
[TBL] [Abstract][Full Text] [Related]
19. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
Ide K; Koshizaka M; Tokuyama H; Tokuyama T; Ishikawa T; Maezawa Y; Takemoto M; Yokote K
Lipids Health Dis; 2018 Mar; 17(1):51. PubMed ID: 29544483
[TBL] [Abstract][Full Text] [Related]
20. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
